Supernus Pharmaceuticals, Inc.
Price Action
Technical Summary
EMERGING TRENDSupernus Pharmaceuticals, Inc. is attempting to emerge into an uptrend but lacks full moving average alignment. Relative strength is weak (RS Rating: 35), showing significant lag compared to the market leaders. Earnings growth of 81% provides fundamental context to the price action. Volume support will be critical for the stock to resolve this consolidation to the upside.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $45.02 | +5.30% | ABOVE |
| 50 SMA | $47.32 | +0.20% | ABOVE |
| 100 SMA | $49.38 | -3.98% | BELOW |
| 150 SMA | $49.16 | -3.56% | BELOW |
| 200 SMA | $48.99 | -3.23% | BELOW |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is SUPN in an uptrend right now?
SUPN has a trend score of 3/4 based on Minervini's Stage Analysis. Currently showing partial alignment - 3 of 4 trend criteria are met.
Is SUPN overbought or oversold?
SUPN's RSI (14) is 54. The stock is in neutral territory, neither overbought nor oversold.
Is SUPN outperforming the market?
SUPN has a Relative Strength (RS) Rating of 35 out of 99. SUPN is currently lagging the broader market.
Where is SUPN in its 52-week range?
SUPN is trading at $47.41, which is 79% of its 52-week high ($59.68) and 57% above its 52-week low ($31.37).
How volatile is SUPN?
SUPN has a Beta of 0.68 and 52-week volatility of 36%. It's less volatile than the S&P 500 - generally more stable.